202 related articles for article (PubMed ID: 26291150)
41. Gamma knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose.
Timmer FC; Hanssens PE; van Haren AE; Mulder JJ; Cremers CW; Beynon AJ; van Overbeeke JJ; Graamans K
Laryngoscope; 2009 Jun; 119(6):1076-81. PubMed ID: 19399836
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome of sensorineural hearing loss in nasopharyngeal carcinoma patients: comparison between treatment with radiotherapy alone and chemoradiotherapy.
Wei Y; Zhou T; Zhu J; Zhang Y; Sun M; Ding X; Wang D; Li H; Li B
Cell Biochem Biophys; 2014 Jul; 69(3):433-7. PubMed ID: 24510513
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
44. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
45. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Recchia F; Saggio G; Cesta A; Amiconi G; di Blasio A; Candeloro G; Valeriani M; Tombolini V; Rea S
Anticancer Res; 2006; 26(3B):2317-24. PubMed ID: 16821609
[TBL] [Abstract][Full Text] [Related]
46. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
[TBL] [Abstract][Full Text] [Related]
47. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
48. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
49. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
50. Concomitant chemoradiotherapy for advanced head and neck cancer.
Lin JC; Jan JS; Hsu CY
Jpn J Clin Oncol; 1994 Apr; 24(2):94-100. PubMed ID: 8158863
[TBL] [Abstract][Full Text] [Related]
51. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
52. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
53. Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study.
Theunissen EA; Zuur CL; Yurda ML; van der Baan S; Kornman AF; de Boer JP; Balm AJ; Rasch CR; Dreschler WA
J Otolaryngol Head Neck Surg; 2014 Aug; 43(1):30. PubMed ID: 25095702
[TBL] [Abstract][Full Text] [Related]
54. Predictors of hearing loss after gamma knife radiosurgery for vestibular schwannomas: age, cochlear dose, and tumor coverage.
Brown M; Ruckenstein M; Bigelow D; Judy K; Wilson V; Alonso-Basanta M; Lee JY
Neurosurgery; 2011 Sep; 69(3):605-13; discussion 613-4. PubMed ID: 21471832
[TBL] [Abstract][Full Text] [Related]
55. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
56. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
57. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
59. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
[TBL] [Abstract][Full Text] [Related]
60. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
